The cell cycle as therapeutic target.
Approved by the FDA in 1991 with indications for acceleration of neutrophil recovery in several clinical settings, CSFs may prove clinically useful in ways beyond hemorestoration. Myeloprotection conferred by GM-CSF may enable higher doses of chemotherapy to be given with only short intervals between cycles. Priming may make resting AML blasts more chemosensitive. Mobilization of peripheral blood stem cells may facilitate and even improve autologous stem cell transplantation.
Broxmeyer
H
H
Walther Oncology Center, Indiana University Medical Center, Indianapolis 46202-5121, USA.
D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D002453:Cell Cycle / Q000187:drug effects*; D002986:Clinical Trials as Topic; D003115:Colony-Stimulating Factors / Q000627:therapeutic use*; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects; D006801:Humans; D009369:Neoplasms / Q000473:pathology / Q000628:therapy*
D003115:Colony-Stimulating Factors; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor